A new study demonstrates the potential of Serum Detect’s T-cell receptor (TCR) repertoire liquid biopsy to complement circulating tumor DNA approaches.
NEWTON, Mass., April 8, 2024 /PRNewswire/ — Serum Detect, Inc., a cancer diagnostics company advancing new technologies for early detection of cancer, today announced the presentation of new data at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The new data suggests that, when combined with circulating tumor DNA (ctDNA) and cancer-related protein biomarkers, Serum Detect’s TCR-based approach may significantly improve sensitivity for the detection of early-stage cancer.
https://www.serumdetect.com/
